| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/ART.30158 |
| P698 | PubMed publication ID | 21360490 |
| P50 | author | Ricardo Blanco | Q73343789 |
| Marek Brzosko | Q92365289 | ||
| P2093 | author name string | Joel M Kremer | |
| Roy Fleischmann | |||
| Ruben Burgos-Vargas | |||
| Emma Vernon | |||
| Anne-Marie Halland | |||
| Petra Ambs | |||
| P433 | issue | 3 | |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| methotrexate | Q422232 | ||
| tocilizumab | Q425154 | ||
| P304 | page(s) | 609-621 | |
| P577 | publication date | 2011-03-01 | |
| P1433 | published in | Arthritis and Rheumatism | Q23929027 |
| P1476 | title | Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year | |
| P478 | volume | 63 |
| Q64241054 | 1,25-Dihydroxyvitamin D3 Ameliorates Collagen-Induced Arthritis via Suppression of Th17 Cells Through miR-124 Mediated Inhibition of IL-6 Signaling |
| Q52675492 | A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases. |
| Q37465508 | A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumato |
| Q55129733 | AC-CUTE: An Open-Label Study to Evaluate Progression of Structural Joint Damage and Inflammation in Subjects with Moderate to Severe Rheumatoid Arthritis. |
| Q21093257 | Advances in rheumatology: new targeted therapeutics |
| Q38431512 | Advances in use of immunomodulatory agents--a rheumatology perspective |
| Q64231019 | Adverse Events in Giant Cell Arteritis and Rheumatoid Arthritis Patient Populations: Analyses of Tocilizumab Clinical Trials and Claims Data |
| Q28071389 | Agranulocytosis under biotherapy in rheumatoid arthritis: three cases hypothesis of parvovirus B19 involvement in agranulocytosis observed under tocilizumab and rituximab for the treatment of rheumatoid arthritis |
| Q34810094 | Alternate virtual populations elucidate the type I interferon signature predictive of the response to rituximab in rheumatoid arthritis |
| Q37465459 | Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials |
| Q101121093 | Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs |
| Q36195284 | Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA). |
| Q30234528 | Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis. |
| Q30235341 | Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis. |
| Q24185797 | Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis |
| Q27021115 | Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement |
| Q36995387 | Bone effects of biologic drugs in rheumatoid arthritis |
| Q58774487 | Bone erosions in rheumatoid arthritis: recent developments in pathogenesis and therapeutic implications |
| Q34563216 | Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment |
| Q36901936 | Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial. |
| Q59329016 | Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries |
| Q28547851 | Comparing Effects of Biologic Agents in Treating Patients with Rheumatoid Arthritis: A Multiple Treatment Comparison Regression Analysis |
| Q35193108 | Comparison of tocilizumab and tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective analysis of 1603 patients managed in routine clinical practice |
| Q33725505 | Concomitant Use of Statins in Tocilizumab-Treated Patients with Rheumatoid Arthritis: A Post Hoc Analysis |
| Q36677277 | Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions |
| Q36996859 | Current perspectives on tocilizumab for the treatment of rheumatoid arthritis: a review |
| Q26782454 | Cytokines and MicroRNAs as Candidate Biomarkers for Systemic Lupus Erythematosus |
| Q90030504 | Cytopenias among patients with rheumatic diseases using methotrexate: a meta-analysis of randomized controlled clinical trials |
| Q38998373 | Differential Effects of Inflammation on Bone and Response to Biologics in Rheumatoid Arthritis and Spondyloarthritis |
| Q27023091 | Drug delivery options to increase patient adherence and satisfaction in the management of rheumatoid arthritis -- focus on subcutaneous tocilizumab |
| Q36481786 | Early changes in blood-based joint tissue destruction biomarkers are predictive of response to tocilizumab in the LITHE study |
| Q42245160 | Effect of biologic therapy on radiological progression in rheumatoid arthritis: what does it add to methotrexate? |
| Q28543128 | Effect of combination therapy on joint destruction in rheumatoid arthritis: a network meta-analysis of randomized controlled trials |
| Q37689966 | Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis |
| Q31151183 | Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials |
| Q64280220 | Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis |
| Q38745362 | Effects of synthetic and biological disease modifying antirheumatic drugs on lipid and lipoprotein parameters in patients with rheumatoid arthritis |
| Q85520686 | Efficacy and safety evaluation of a combination of iguratimod and methotrexate therapy for active rheumatoid arthritis patients: a randomized controlled trial |
| Q96298839 | Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies |
| Q40447501 | Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. |
| Q92737348 | Efficacy and safety of subcutaneous tocilizumab in rheumatoid arthritis over 1 year: a UK real-world, open-label study |
| Q42090806 | Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA) |
| Q61453693 | Efficacy and safety of various anti-rheumatic treatments for patients with rheumatoid arthritis: a network meta-analysis |
| Q36246068 | Evaluating joint-space narrowing and cartilage loss in rheumatoid arthritis by using MRI. |
| Q35258244 | Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry |
| Q92106905 | IL-6 Mediated Transcriptional Programming of Naïve CD4+ T Cells in Early Rheumatoid Arthritis Drives Dysregulated Effector Function |
| Q38261783 | IL-6 blockade in chronic inflammatory diseases |
| Q37121710 | IL-6 pathway-driven investigation of response to IL-6 receptor inhibition in rheumatoid arthritis |
| Q34640584 | IL-6 stimulates intestinal epithelial proliferation and repair after injury |
| Q33921579 | Identification of differential co-expressed gene networks in early rheumatoid arthritis achieving sustained drug-free remission after treatment with a tocilizumab-based or methotrexate-based strategy |
| Q98564934 | Identification of heterogenous treatment response trajectories to anti-IL6 receptor treatment in rheumatoid arthritis |
| Q92146862 | Identification of pathological RA endotypes using blood-based biomarkers reflecting tissue metabolism. A retrospective and explorative analysis of two phase III RA studies |
| Q36252760 | Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study |
| Q37358271 | Incidence density of serious infection, opportunistic infection, and tuberculosis associated with biologic treatment in patients with rheumatoid arthritis - a systematic evaluation of the literature |
| Q31137082 | Incidence of Gastrointestinal Perforations in Patients with Rheumatoid Arthritis Treated with Tocilizumab from Clinical Trial, Postmarketing, and Real-World Data Sources |
| Q52312175 | Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. |
| Q26752511 | Inflammation Meets Metabolic Disease: Gut Feeling Mediated by GLP-1 |
| Q37989394 | Inflammatory bone loss: pathogenesis and therapeutic intervention |
| Q38197519 | Inhibition of the interleukin-6 signaling pathway: a strategy to induce immune tolerance |
| Q35840716 | Integrated safety in tocilizumab clinical trials |
| Q58093374 | Intensive therapy and remissions in rheumatoid arthritis: a systematic review |
| Q37553940 | Interleukin 6 and rheumatoid arthritis |
| Q90117830 | Interleukin-6 inhibition in the management of non-infectious uveitis and beyond |
| Q41901416 | Interleukin-6 is elevated in synovial fluid of patients with focal cartilage defects and stimulates cartilage matrix production in an in vitro regeneration model |
| Q92582667 | Interleukin-6 neutralization prolongs corneal allograft survival |
| Q36682022 | Interleukin-6 receptor blockade selectively reduces IL-21 production by CD4 T cells and IgG4 autoantibodies in rheumatoid arthritis |
| Q36492279 | Interpreting the multi-biomarker disease activity score in the context of tocilizumab treatment for patients with rheumatoid arthritis |
| Q94661081 | Intestinal perforation in patient with COVID-19 infection treated with tocilizumab and corticosteroids. Report of a clinical case |
| Q39129914 | Macrophages and skeletal health |
| Q36919914 | Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab |
| Q35618458 | Management of rheumatoid arthritis in People's Republic of China - focus on tocilizumab and patient considerations |
| Q89425568 | Mapping between HAQ-DI and EQ-5D-5L in a Chinese patient population |
| Q33754764 | Matrix Metalloproteinase Gene Activation Resulting from Disordred Epigenetic Mechanisms in Rheumatoid Arthritis. |
| Q37536373 | Mechanism-based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study). |
| Q38939820 | Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis. |
| Q33765689 | Monitoring cartilage loss in the hands and wrists in rheumatoid arthritis with magnetic resonance imaging in a multi-center clinical trial: IMPRESS (NCT00425932). |
| Q26824970 | Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors |
| Q47692825 | Neuroendocrine and neurophysiological effects of interleukin 6 in rheumatoid arthritis |
| Q55360477 | Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis. |
| Q34477442 | Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis. |
| Q30699616 | Phase IV non-interventional studies in the treatment of rheumatoid arthritis with biologicals in Germany : real-life clinical practice data |
| Q52351586 | Previously reported placebo-response-associated variants do not predict patient outcomes in inflammatory disease Phase III trial placebo arms. |
| Q38745066 | Profile of sarilumab and its potential in the treatment of rheumatoid arthritis. |
| Q49215677 | Profile of tocilizumab and its potential in the treatment of giant cell arteritis. |
| Q89584902 | Real-World Dose Modification Patterns of Subcutaneous Tocilizumab Among Patients with Rheumatoid Arthritis |
| Q58109529 | Real-World Tocilizumab Use in Patients with Rheumatoid Arthritis in Canada: 12-Month Results From an Observational, Noninterventional Study |
| Q27686770 | Regulation of B lymphocytes and plasma cells by innate immune mechanisms and stromal cells in rheumatoid arthritis |
| Q40423985 | Relationship Between Baseline and Early Changes in C-Reactive Protein and Interleukin-6 Levels and Clinical Response to Tocilizumab in Rheumatoid Arthritis |
| Q64888081 | Retention of tocilizumab with and without methotrexate during maintenance therapy for rheumatoid arthritis: the ACTRA-RI cohort study. |
| Q33809045 | Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics |
| Q38234629 | Rituximab and tocilizumab for the treatment of rheumatoid arthritis |
| Q38910201 | Room for more IL-6 blockade? Sarilumab for the treatment of rheumatoid arthritis |
| Q97537418 | SAFETY AND EFFICACY OF ANTI-IL6-RECEPTOR TOCILIZUMAB USE IN SEVERE AND CRITICAL PATIENTS AFFECTED BY CORONAVIRUS DISEASE 2019: A COMPARATIVE ANALYSIS |
| Q42578542 | Safety and efficacy of tocilizumab for the treatment of rheumatoid arthritis |
| Q35674568 | Safety, Tolerability, and Efficacy of Tocilizumab in Rheumatoid Arthritis: An Open-Label Phase 4 Study in Patients from the Middle East |
| Q39176539 | Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors |
| Q37704288 | Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors |
| Q34092311 | Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial |
| Q34134566 | Serological biomarkers of joint tissue turnover predict tocilizumab response at baseline |
| Q37689708 | Serological identification of fast progressors of structural damage with rheumatoid arthritis. |
| Q40374825 | Short-Term Efficacy Reliably Predicts Long-Term Clinical Benefit in Rheumatoid Arthritis Clinical Trials as Demonstrated by Model-Based Meta-Analysis |
| Q26852081 | Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis |
| Q42547820 | Structural Mimicry of Receptor Interaction by Antagonistic Interleukin-6 (IL-6) Antibodies. |
| Q49824861 | Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries |
| Q34770459 | Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis |
| Q37320282 | Sustainable Efficacy of Switching From Intravenous to Subcutaneous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis |
| Q33400381 | Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor |
| Q38086137 | Targeting interleukin-6 in rheumatoid arthritis |
| Q55137324 | The Efficacy and Safety of Mainstream Medications for Patients With cDMARD-Naïve Rheumatoid Arthritis: A Network Meta-Analysis. |
| Q37715992 | The effects of tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: results from the ACT-RAY MRI substudy |
| Q35864053 | The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis |
| Q48029200 | The pathogenesis of rheumatoid arthritis: new insights from old clinical data? |
| Q39215645 | The role of interleukin-6 signalling and its therapeutic blockage in skewing the T cell balance in rheumatoid arthritis. |
| Q35429154 | The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis |
| Q47978774 | Tocilizumab (Actemra). |
| Q37278384 | Tocilizumab as monotherapy or combination therapy for treating active rheumatoid arthritis: a meta-analysis of efficacy and safety reported in randomized controlled trials |
| Q41146132 | Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial |
| Q33432572 | Tocilizumab efficacy and safety in rheumatoid arthritis patients after inadequate response to disease-modifying anti-rheumatic drugs oranti-tumor necrosis factor |
| Q35724900 | Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions |
| Q36968747 | Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial |
| Q38110210 | Tocilizumab in pediatric rheumatology: the clinical experience |
| Q36515498 | Tocilizumab in rheumatoid arthritis: efficacy, safety and its place in therapy |
| Q37682799 | Tocilizumab in the treatment of rheumatoid arthritis and beyond |
| Q60300744 | Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection |
| Q42540679 | Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction |
| Q44165611 | Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial |
| Q37358242 | Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for treatment of rheumatoid arthritis |
| Q43280791 | Tocilizumab: A Review in Rheumatoid Arthritis |
| Q41933635 | Tocilizumab: a novel humanized anti-interleukin 6 receptor antibody for the treatment of patients with rheumatoid arthritis |
| Q93196330 | Translating IL-6 biology into effective treatments |
| Q41450339 | Treatment comparison in rheumatoid arthritis: head-to-head trials and innovative study designs |
| Q42054025 | Variation at interleukin-6 receptor gene is associated to joint damage in rheumatoid arthritis |
| Q84582827 | [Local and systemic bone effects of rheumatoid arthritis] |
Search more.